Clinical trials assessing PDE5 inhibitors for DMD patients are currently underway, and future use of tadalafil or sildenafil for these individuals seems promising based on preclinical studies and current clinical availability of these drugs for their use in treating erectile dysfunction and pulmonary hypertension. Here, PDE5A is linked to Duchenne muscular dystrophy.